MK-677 (Ibutamoren) Research: The Non-Peptide Secretagogue and What Its Trials Measured

What is MK-677?

What is MK-677? It is a synthetic non-peptide small molecule — a spiroindane-based peptidomimetic of roughly 529 daltons — that acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor. Its International Nonproprietary Name is ibutamoren; in the Merck literature it appears as MK-0677 and as the development code L-163,191. It is commonly supplied and studied as the mesylate salt, ibutamoren mesylate.

The point worth being blunt about is the one most often got wrong: MK-677 is filed alongside GHRP-2, GHRP-6, hexarelin and ipamorelin because it hits the same receptor, not because it resembles them chemically. It has no amino acids, no peptide bonds and no sequence. Vendor catalogues that list it as a peptide are describing its pharmacological family and mislabelling its chemistry — which also means it is stored, handled and analysed as a small molecule rather than as a peptide. Everything below describes chemistry, receptor pharmacology and what published trials measured.

Discovery and origin in the literature

The problem the chemistry was solving

By the early 1990s the growth-hormone-releasing peptides had established that GHS-R1a was a real and druggable target, but short peptides are poorly absorbed from the gut and rapidly cleared. Merck set out to find a non-peptide that would do the same job orally. Smith and colleagues reported the first result in Science in 1993 (PMID 8503009) — “A nonpeptidyl growth hormone secretagogue” — establishing that the receptor could be engaged by something that was not a peptide at all.

MK-0677 (1995)

Patchett and colleagues reported the optimised compound in Proc Natl Acad Sci USA in 1995 (PMID 7624358), under a title that states the design goal exactly: the design and biological activities of L-163,191 (MK-0677), a potent, orally active growth hormone secretagogue. This is a designed molecule with a documented medicinal-chemistry lineage — a different provenance from the GHRPs, which came out of empirical peptide screening, and from sermorelin, which is a fragment of a natural hormone.

Reference data

Identity facts from the public chemical record (PubChem CID 178024) and standard catalogue data. There is no sequence row below, because there is no sequence — this is not a peptide. Fields that could not be sourced are omitted rather than estimated.

Two analytical consequences follow from the chemistry. First, the identity check on a batch is a small-molecule check — HPLC with UV detection against a reference standard, and mass spectrometry against 528.7 Da for the free base — not the peptide-mapping logic used elsewhere in this catalogue. Second, because MK-677 is routinely supplied as the mesylate salt, a certificate should be read carefully for which form the reported mass and content refer to; free base and salt are different numbers for the same substance. No solubility row appears above because a sourced value for the research material was not available, and this page does not estimate one. Molecule and analytical facts only.

Mechanisms researchers have examined

The MK-677 mechanism is the ghrelin-receptor mechanism, reached by a different chemical route. Each point is what studies characterised:

• GHS-R1a agonism — MK-677 activates the same Gq-coupled receptor in pituitary and hypothalamus that the GHRP peptides act at, signalling through phospholipase C and calcium mobilisation.
• Oral bioavailability by design — the property Patchett et al. (1995) set out to achieve, and the single feature that separates this molecule from every peptide in the family. It is a pharmacokinetic characteristic, not an efficacy claim.
• Sustained elevation of the GH/IGF-1 axis — Chapman et al. (1997, J Clin Endocrinol Metab, PMID 9329386) measured stimulation of the growth-hormone / IGF-1 axis after oral administration in selected growth-hormone-deficient adults. Later trials quantified the same target engagement: Sevigny et al. (2008) reported serum IGF-1 rising roughly 60% at six weeks and 73% at twelve months; Adunsky et al. (2011) reported an 84% increase against 17% on placebo.
• Effects beyond the somatotroph axis — Nass et al. (2008) measured increases in cortisol, a rise in fasting blood glucose and decreased insulin sensitivity alongside the intended endocrine changes. Reported as measured trial findings, without characterising them further.

The receptor MK-677 acts at is not the receptor sermorelin, CJC-1295 and tesamorelin act at. Those are GHRH analogues at the GHRH receptor; this is a ghrelin-receptor agonist. Mechanism contrast only, not a combination.

Research findings by area

MK-677 was taken into real randomised trials across four separate questions, and reading them together is more informative than any one of them:

• Nitrogen balance — Murphy et al. (1998, J Clin Endocrinol Metab, PMID 9467534) reported that MK-677 reversed diet-induced nitrogen wasting in a short-term study, and the authors framed the finding conditionally: if such short-term effects were maintained in catabolic patients, the compound might be useful in catabolic conditions. That conditional was the hypothesis the later trials went on to test.
• Sleep architecture — Copinschi et al. (1997, Neuroendocrinology, PMID 9349662) examined sleep parameters during prolonged oral treatment in men. This is an older, small polysomnographic study and is cited here for what it measured.
• Hip-fracture recovery — tested twice. Bach et al. (2004, J Am Geriatr Soc, PMID 15066065) reported no significant differences from placebo in functional performance measures or overall score, concluding it was uncertain whether clinically significant effects on physical function were achieved. Adunsky et al. (2011, Arch Gerontol Geriatr, PMID 21067829) ran a multicentre randomised placebo-controlled phase-IIb study in the same population, again with IGF-1 clearly raised.
• Alzheimer’s disease progression — the largest trial in the programme. Sevigny et al. (2008, Neurology, PMID 19015485) randomised 563 patients with mild-to-moderate Alzheimer’s disease for twelve months. Serum IGF-1 rose substantially, and there were no significant differences between treatment groups on any of the four efficacy measures. The paper’s stated conclusion: despite evidence of target engagement, MK-677 was ineffective at slowing the rate of progression.

The two-year trial in healthy older adults

Nass et al. (2008, Ann Intern Med, PMID 18981485) is the study most often cited for this compound, and it deserves to be reported in full rather than in the half that suits a sales page. It was a two-year, double-blind, randomised, placebo-controlled, modified-crossover trial in 65 healthy adults aged 60–81. Growth hormone and IGF-1 rose into a young-adult range. Mean fat-free mass decreased in the placebo group and increased in the MK-677 group, a statistically significant difference, and body weight rose more in the treatment group.

The same paper reports the rest. Abdominal visceral fat and total fat mass showed no significant difference between groups; the average increase in limb fat was greater on MK-677. Fasting blood glucose rose and insulin sensitivity decreased. Cortisol increased. The most frequent side effects reported were an increase in appetite that subsided over months, and transient mild lower-extremity oedema and muscle pain. And, in the authors’ own sentence, the increased fat-free mass did not result in changes in strength or function. The trial’s stated limitation was that its power was insufficient to evaluate functional endpoints. That is the complete finding, and this page reports it complete.

Research models and evidence status

MK-677 has been studied more rigorously than anything else in this cluster, and the shape of the result is consistent across indications: the molecule reliably engages its target and raises IGF-1 by large, reproducible margins, and the clinical endpoints built on top of that engagement were not met. Two hip-fracture trials did not demonstrate functional benefit. A 563-patient Alzheimer’s trial was explicitly negative. A two-year trial in healthy older adults increased fat-free mass without a change in strength or function.

What is not established

There is no approved product containing ibutamoren, and no registered indication anywhere. Raising IGF-1 is demonstrated; translating that into a functional, cognitive or clinical outcome is not. Body-composition and anti-ageing claims commonly attached to this compound are not supported by the trials cited here — the trial designed to test exactly that question reported no change in strength or function, and this page makes no such claim. The metabolic findings reported alongside the intended effects (rising fasting glucose, decreased insulin sensitivity, increased cortisol) are part of the same published record and are stated here because omitting them would misrepresent it. No long-term safety dataset exists outside these trial populations.

On anti-doping status, reported as fact and not as a use case: growth-hormone secretagogues, including non-peptide agents of this class, appear under section S2 of the World Anti-Doping Agency Prohibited List and are prohibited at all times, in and out of competition. Ibutamoren and its metabolites are an active subject of analytical-toxicology method development for that reason.

MK-677 among the secretagogues

Placed in the family, MK-677 is the outlier on chemistry and the standard-setter on evidence. The peptides at this receptor — GHRP-6, GHRP-2, hexarelin, ipamorelin — have mechanistic literatures and, at most, small or short human studies. MK-677 has multi-hundred-patient randomised trials with published negative results, which is a far more useful thing to know about a compound than another receptor-binding paper. The GHRH analogues (sermorelin, CJC-1295, tesamorelin) sit on the other receptor entirely, and of those only tesamorelin carries a comparable trial programme.

A pattern runs across this whole cluster and is worth naming once: where the growth-hormone axis has been stimulated and functional outcomes have then been measured properly — MK-677’s trials, hexarelin’s sixteen-week study, GHRP-2’s five-day study — the endocrine change has been easier to produce than the outcome. Reporting that is not a judgement on the compounds; it is the literature. Receptor-family context only; nothing here is a protocol, a stack or a recommendation.

How to verify this compound yourself

Because MK-677 is a small molecule rather than a peptide, the verification logic differs from the rest of the catalogue:

• HPLC purity against a reference standard — reversed-phase chromatography with UV detection separates the compound from process impurities and degradants and reports purity as a percentage. For a defined small molecule, retention time against a known standard is itself part of the identity evidence, which is not true in the same way for peptides.
• Mass-spec identity — the measured mass is checked against ≈ 528.7 Da for the free base. Note the salt question here: a certificate reporting the mesylate will not report the same mass, and a lot claimed as free base should be consistent with the free-base figure.
• What a small-molecule certificate does not need — endotoxin and sterility are attributes that matter for material intended for parenteral use; an orally studied small molecule is not usually characterised that way. Reading a certificate means reading which attributes were actually tested rather than assuming a template.

See how to read a COA for what each line on a certificate means, how to verify peptide purity for how HPLC and mass spec fit together, and the self-serve verify tool to check the exact batch on a vial in hand.

Research-grade sourcing and verification

For laboratory research use only. MK-677 is not held in stock; it is listed as available to order in the sourcing catalogue, with a typical lead time of two to three weeks and a quote on request. Material supplied ships with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level, and — given the free-base-versus-mesylate question above — the form the certificate refers to is worth reading before anything else. Sourcing and identity-assurance framing only; nothing here speaks to outcomes.

Frequently asked questions

Literature cited

1. Smith RG, Cheng K, Schoen WR, et al. “A nonpeptidyl growth hormone secretagogue.” Science. 1993;260(5114):1640–1643. PMID 8503009. pubmed.ncbi.nlm.nih.gov/8503009.
2. Patchett AA, Nargund RP, Tata JR, et al. “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.” Proc Natl Acad Sci U S A. 1995;92(15):7001–7005. PMID 7624358. pubmed.ncbi.nlm.nih.gov/7624358.
3. Chapman IM, Bach MA, Van Cauter E, et al. “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.” J Clin Endocrinol Metab. 1997;82(10):3455–3463. PMID 9329386. pubmed.ncbi.nlm.nih.gov/9329386.
4. Copinschi G, Leproult R, Van Onderbergen A, et al. “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.” Neuroendocrinology. 1997;66(4):278–286. PMID 9349662. pubmed.ncbi.nlm.nih.gov/9349662.
5. Murphy MG, Plunkett LM, Gertz BJ, et al. “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.” J Clin Endocrinol Metab. 1998;83(2):320–325. PMID 9467534. pubmed.ncbi.nlm.nih.gov/9467534.
6. Bach MA, Rockwood K, Zetterberg C, et al. “The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.” J Am Geriatr Soc. 2004;52(4):516–523. PMID 15066065. pubmed.ncbi.nlm.nih.gov/15066065.
7. Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601–611. PMID 18981485. pubmed.ncbi.nlm.nih.gov/18981485.
8. Sevigny JJ, Ryan JM, van Dyck CH, et al. “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.” Neurology. 2008;71(21):1702–1708. PMID 19015485. pubmed.ncbi.nlm.nih.gov/19015485.
9. Adunsky A, Chandler J, Heyden N, et al. “MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.” Arch Gerontol Geriatr. 2011;53(2):183–189. PMID 21067829. pubmed.ncbi.nlm.nih.gov/21067829.
10. National Center for Biotechnology Information. “PubChem Compound Summary for CID 178024, Ibutamoren.” pubchem.ncbi.nlm.nih.gov/compound/178024 (formula, mass, CAS 159634-47-6 free base).
11. World Anti-Doping Agency. “The Prohibited List” — section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org/en/prohibited-list.